O	0	16	Lysophosphatidic	Lysophosphatidic	JJ	B-NP
O	17	21	acid	acid	NN	I-NP
O	22	35	downregulates	downregulate	VBZ	B-VP
O	36	42	tissue	tissue	NN	B-NP
O	43	52	inhibitor	inhibitor	NN	I-NP
O	53	55	of	of	IN	B-PP
O	56	74	metalloproteinases	metalloproteinas	NNS	B-NP
O	74	75	,	,	,	O
O	76	81	which	which	WDT	B-NP
O	82	85	are	be	VBP	B-VP
O	86	96	negatively	negatively	RB	I-VP
O	97	105	involved	involve	VBN	I-VP
O	106	108	in	in	IN	B-PP
O	109	125	lysophosphatidic	lysophosphatidic	JJ	B-NP
O	126	130	acid	acid	NN	I-NP
O	130	131	-	-	HYPH	B-NP
O	131	138	induced	induce	VBN	I-NP
B-Cell	139	143	cell	cell	NN	I-NP
O	144	152	invasion	invasion	NN	I-NP
O	152	153	.	.	.	O

B-Cancer	155	162	Ovarian	Ovarian	JJ	B-NP
I-Cancer	163	169	cancer	cancer	NN	I-NP
O	170	172	is	be	VBZ	B-VP
O	173	174	a	a	DT	B-NP
O	175	181	highly	highly	RB	I-NP
O	182	192	metastatic	metastatic	JJ	I-NP
O	193	200	disease	disease	NN	I-NP
O	200	201	.	.	.	O

O	202	218	Lysophosphatidic	Lysophosphatidic	JJ	B-NP
O	219	223	acid	acid	NN	I-NP
O	224	225	(	(	(	O
O	225	228	LPA	LPA	NN	B-NP
O	228	229	)	)	)	O
O	230	236	levels	level	NNS	B-NP
O	237	240	are	be	VBP	B-VP
O	241	249	elevated	elevate	VBN	I-VP
O	250	252	in	in	IN	B-PP
B-Organism_substance	253	260	ascites	ascite	NNS	B-NP
O	261	265	from	from	IN	B-PP
B-Cancer	266	273	ovarian	ovarian	JJ	B-NP
I-Cancer	274	280	cancer	cancer	NN	I-NP
O	281	289	patients	patient	NNS	I-NP
O	289	290	,	,	,	O
O	291	294	but	but	CC	O
O	295	298	its	its	PRP$	B-NP
O	299	308	potential	potential	JJ	I-NP
O	309	313	role	role	NN	I-NP
O	314	316	in	in	IN	B-PP
B-Cancer	317	324	ovarian	ovarian	JJ	B-NP
I-Cancer	325	331	cancer	cancer	NN	I-NP
O	332	342	metastasis	metastasis	NN	I-NP
O	343	346	has	have	VBZ	B-VP
O	347	351	just	just	RB	I-VP
O	352	357	begun	begin	VBN	I-VP
O	358	360	to	to	TO	I-VP
O	361	363	be	be	VB	I-VP
O	364	372	revealed	reveal	VBN	I-VP
O	372	373	.	.	.	O

O	374	376	In	In	IN	B-PP
O	377	381	this	this	DT	B-NP
O	382	386	work	work	NN	I-NP
O	386	387	,	,	,	O
O	388	390	we	we	PRP	B-NP
O	391	395	show	show	VBP	B-VP
O	396	400	that	that	IN	B-SBAR
O	401	404	LPA	LPA	NN	B-NP
O	405	415	stimulates	stimulate	VBZ	B-VP
O	416	424	invasion	invasion	NN	B-NP
O	425	427	of	of	IN	B-PP
B-Cell	428	435	primary	primary	JJ	B-NP
I-Cell	436	443	ovarian	ovarian	JJ	I-NP
I-Cell	444	450	cancer	cancer	NN	I-NP
I-Cell	451	456	cells	cell	NNS	I-NP
O	456	457	,	,	,	O
O	458	461	but	but	CC	O
O	462	465	not	not	RB	O
B-Cell	466	473	ovarian	ovarian	JJ	B-NP
I-Cell	474	484	epithelial	epithelial	JJ	I-NP
O	485	487	or	or	CC	I-NP
B-Cell	488	498	borderline	borderline	JJ	I-NP
I-Cell	499	506	ovarian	ovarian	JJ	I-NP
I-Cell	507	512	tumor	tumor	NN	I-NP
I-Cell	513	518	cells	cell	NNS	I-NP
O	518	519	,	,	,	O
O	520	528	although	although	IN	B-SBAR
O	529	534	these	these	DT	B-NP
B-Cell	535	541	benign	benign	JJ	I-NP
I-Cell	542	547	cells	cell	NNS	I-NP
O	548	554	indeed	indeed	RB	B-ADVP
O	555	562	respond	respond	VBP	B-VP
O	563	565	to	to	TO	B-PP
O	566	569	LPA	LPA	NN	B-NP
O	570	572	in	in	IN	B-PP
B-Cell	573	577	cell	cell	NN	B-NP
O	578	587	migration	migration	NN	I-NP
O	587	588	.	.	.	O

O	589	591	We	We	PRP	B-NP
O	592	596	have	have	VBP	B-VP
O	597	602	found	find	VBN	I-VP
O	603	607	that	that	IN	B-SBAR
O	608	611	LPA	LPA	NN	B-NP
O	612	625	downregulates	downregulate	VBZ	B-VP
O	626	632	tissue	tissue	NN	B-NP
O	633	642	inhibitor	inhibitor	NN	I-NP
O	643	645	of	of	IN	B-PP
O	646	664	metalloproteinases	metalloproteinas	NNS	B-NP
O	665	666	(	(	(	O
O	666	671	TIMPs	TIMP	NNS	B-NP
O	671	672	)	)	)	O
O	672	673	.	.	.	O

O	674	679	TIMP2	TIMP2	NN	B-NP
O	680	683	and	and	CC	I-NP
O	684	689	TIMP3	TIMP3	NN	I-NP
O	690	694	play	play	VBP	B-VP
O	695	705	functional	functional	JJ	B-NP
O	706	710	role	role	NN	I-NP
O	711	713	in	in	IN	B-PP
O	714	717	LPA	LPA	NN	B-NP
O	717	718	-	-	HYPH	B-NP
O	718	725	induced	induce	VBN	I-NP
O	726	734	invasion	invasion	NN	I-NP
O	735	737	as	as	IN	B-PP
O	738	746	negative	negative	JJ	B-NP
O	747	757	regulators	regulator	NNS	I-NP
O	757	758	.	.	.	O

O	759	760	G	G	NN	B-NP
O	760	761	(	(	(	O
O	761	762	i	i	NN	B-NP
O	762	763	)	)	)	O
O	764	771	protein	protein	NN	B-NP
O	771	772	,	,	,	O
O	773	793	phosphatidylinositol	phosphatidylinositol	NN	B-NP
O	793	794	-	-	HYPH	O
O	794	795	3	3	CD	B-NP
O	796	802	kinase	kinase	NN	I-NP
O	803	804	(	(	(	O
O	804	808	PI3K	PI3K	NN	B-NP
O	808	809	)	)	)	O
O	809	810	,	,	,	O
O	811	814	p38	p38	NN	B-NP
O	815	822	mitogen	mitogen	NN	I-NP
O	822	823	-	-	HYPH	B-VP
O	823	832	activated	activate	VBN	B-NP
O	833	840	protein	protein	NN	I-NP
O	841	847	kinase	kinase	NN	I-NP
O	848	849	(	(	(	O
O	849	853	MAPK	MAPK	NN	B-NP
O	853	854	)	)	)	O
O	854	855	,	,	,	O
B-Organism_substance	856	865	cytosolic	cytosolic	JJ	B-NP
O	866	879	phospholipase	phospholipase	NN	I-NP
O	880	881	A	A	NN	I-NP
O	881	882	(	(	(	O
O	882	883	2	2	CD	B-NP
O	883	884	)	)	)	O
O	885	888	and	and	CC	O
O	889	898	urokinase	urokinase	NN	B-NP
O	899	903	type	type	NN	I-NP
O	904	915	plasminogen	plasminogen	NN	I-NP
O	916	925	activator	activator	NN	I-NP
O	926	927	(	(	(	O
O	927	930	uPA	uPA	NN	B-NP
O	930	931	)	)	)	O
O	932	935	are	be	VBP	B-VP
O	936	944	required	require	VBN	I-VP
O	945	948	for	for	IN	B-PP
O	949	952	LPA	LPA	NN	B-NP
O	952	953	-	-	HYPH	B-NP
O	953	960	induced	induce	VBN	I-NP
B-Cell	961	966	cells	cell	NNS	I-NP
O	967	975	invasion	invasion	NN	I-NP
O	975	976	.	.	.	O

O	977	982	TIMP3	TIMP3	NN	B-NP
O	983	986	may	may	MD	B-VP
O	987	993	affect	affect	VB	I-VP
O	994	997	two	two	CD	B-NP
O	998	1009	independent	independent	JJ	I-NP
O	1010	1020	downstream	downstream	JJ	I-NP
O	1021	1028	targets	target	NNS	I-NP
O	1028	1029	,	,	,	O
O	1030	1038	vascular	vascular	JJ	B-NP
O	1039	1050	endothelial	endothelial	JJ	I-NP
O	1051	1057	growth	growth	NN	I-NP
O	1058	1064	factor	factor	NN	I-NP
O	1065	1073	receptor	receptor	NN	I-NP
O	1074	1077	and	and	CC	O
O	1078	1081	p38	p38	NN	B-NP
O	1082	1086	MAPK	MAPK	NN	I-NP
O	1086	1087	.	.	.	O

O	1088	1090	In	In	FW	B-ADVP
O	1091	1095	vivo	vivo	FW	I-ADVP
O	1095	1096	,	,	,	O
O	1097	1100	LPA	LPA	NN	B-NP
O	1101	1111	stimulates	stimulate	VBZ	B-VP
B-Cancer	1112	1117	tumor	tumor	NN	B-NP
O	1118	1128	metastasis	metastasis	NN	I-NP
O	1129	1131	in	in	IN	B-PP
O	1132	1134	an	an	DT	B-NP
O	1135	1145	orthotopic	orthotopic	JJ	I-NP
B-Cancer	1146	1153	ovarian	ovarian	JJ	I-NP
I-Cancer	1154	1159	tumor	tumor	NN	I-NP
O	1160	1165	model	model	NN	I-NP
O	1165	1166	,	,	,	O
O	1167	1172	which	which	WDT	B-NP
O	1173	1176	can	can	MD	B-VP
O	1177	1179	be	be	VB	I-VP
O	1180	1189	inhibited	inhibit	VBN	I-VP
O	1190	1192	by	by	IN	B-PP
O	1193	1194	a	a	DT	B-NP
O	1195	1199	PI3K	PI3K	NN	I-NP
O	1200	1209	inhibitor	inhibitor	NN	I-NP
O	1209	1210	,	,	,	O
O	1211	1219	LY294002	LY294002	NN	B-NP
O	1219	1220	.	.	.	O

O	1221	1223	In	In	IN	B-PP
O	1224	1231	summary	summary	NN	B-NP
O	1231	1232	,	,	,	O
O	1233	1236	LPA	LPA	NN	B-NP
O	1237	1239	is	be	VBZ	B-VP
O	1240	1246	likely	likely	RB	B-ADJP
O	1247	1248	a	a	DT	B-NP
O	1249	1252	key	key	JJ	I-NP
O	1253	1262	component	component	NN	I-NP
O	1263	1266	for	for	IN	B-PP
O	1267	1276	promoting	promote	VBG	B-VP
B-Organ	1277	1284	ovarian	ovarian	JJ	B-NP
O	1285	1295	metastasis	metastasis	NN	I-NP
O	1296	1298	in	in	FW	B-ADVP
O	1299	1303	vivo	vivo	FW	I-ADVP
O	1303	1304	.	.	.	O

O	1305	1308	LPA	LPA	NN	B-NP
O	1309	1322	downregulates	downregulate	VBZ	B-VP
O	1323	1328	TIMP3	TIMP3	NN	B-NP
O	1328	1329	,	,	,	O
O	1330	1335	which	which	WDT	B-NP
O	1336	1339	may	may	MD	B-VP
O	1340	1344	have	have	VB	I-VP
O	1345	1352	targets	target	NNS	B-NP
O	1353	1358	other	other	JJ	B-ADJP
O	1359	1363	than	than	IN	B-PP
O	1364	1382	metalloproteinases	metalloproteinas	NNS	B-NP
O	1382	1383	.	.	.	O

O	1384	1387	Our	Our	PRP$	B-NP
O	1388	1390	in	in	FW	I-NP
O	1391	1395	vivo	vivo	FW	I-NP
O	1396	1406	metastasis	metastasis	NN	I-NP
O	1407	1412	mouse	mouse	NN	I-NP
O	1413	1418	model	model	NN	I-NP
O	1419	1421	is	be	VBZ	B-VP
O	1422	1428	useful	useful	JJ	B-ADJP
O	1429	1432	for	for	IN	B-PP
O	1433	1441	studying	study	VBG	B-VP
O	1442	1445	the	the	DT	B-NP
O	1446	1454	efficacy	efficacy	NN	I-NP
O	1455	1457	of	of	IN	B-PP
O	1458	1469	therapeutic	therapeutic	JJ	B-NP
O	1470	1477	regimes	regime	NNS	I-NP
O	1478	1480	of	of	IN	B-PP
B-Cancer	1481	1488	ovarian	ovarian	JJ	B-NP
I-Cancer	1489	1495	cancer	cancer	NN	I-NP
O	1495	1496	.	.	.	O

